The effect of adjuvant tislelizumab plus chemotherapy on failure free survival after post-operative pelvic chemoradiation in high risk endometrial cancer – ADELE: a randomised phase 2 trial
ACTRN 12621000273886 Brief Summary The ADELE clinical trial seeks to improve outcomes…
Read more arrow_forward